Table 1.

Antimycotic-susceptibility profiles of clinical C. albicans used in our study.

Candida albicans clinical strains	MIC values (μg/mL) of antifungal agenta
	AND	MF	CAS	PZ	VOR	IZ	FZ	AB
Ca1	1 (R)	4 (R)	2 (R)	0.25 (R)	0.5 (I)	0.25 (R)	64 (R)	0.5 (S)
Ca2	0.015 (S)	0.008 (S)	0.015 (S)	1 (R)	0.5 (I)	0.5 (R)	64 (R)	0.12 (S)
Ca3	0.03 (S)	0.008 (S)	0.06 (S)	8 (R)	>8 (R)	16 (R)	128 (R)	0.5 (S)
Ca4	0.06 (S)	0.125 (S)	0.06 (S)	1 (R)	8 (R)	16 (R)	128 (R)	0.5 (S)
Ca5	0.12 (S)	0.5 (I)	0.12 (S)	0.125 (R)	0.015 (S)	0.12 (R)	0.25 (S)	2 (R)
Ca6	1 (R)	1 (R)	0.5 (I)	0.125 (R)	0.03 (S)	0.12 (R)	1 (S)	0.5 (S)

^aAND: anidulafungin; MF: micafungin; CAS: caspofungin; PZ: posaconazole¹; VOR: voriconazole; IZ: itraconazole; FZ: fluconazole; AB: amphotericin B¹, R, Resistant; S, Susceptible, I, intermediate. MIC values interpretated with clinical breakpoint EUCAST (version 10.0).